Allergan price target raised to $145 from $122 at Susquehanna Susquehanna raised its price target on Allergan following its patent win on Lumigan. the firm believes the company deserves a premium valuation citing its reduced threat to near-term earnings, its financial strength, and expectation of accretive deals. Shares are Positive rated.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.